Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H14ClN3O4S3 |
Molecular Weight | 431.937 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC3=CC=CC=C3)NS2(=O)=O
InChI
InChIKey=NDTSRXAMMQDVSW-UHFFFAOYSA-N
InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.tabletwise.com/us/exna-tablet | http://edudrugs.com/A/Aquatag/more.html | https://www.drugs.com/uk/dytide-capsules-leaflet.html | http://www.tabletwise.com/us/exna-tablet
Curator's Comment: description was created based on several sources, including:
http://www.tabletwise.com/us/exna-tablet | http://edudrugs.com/A/Aquatag/more.html | https://www.drugs.com/uk/dytide-capsules-leaflet.html | http://www.tabletwise.com/us/exna-tablet
Benzthiazide (trade names Aquatag, Dihydrex, Diucen, Edemax, Exna, Foven and others) is a thiazide diuretic used in the treatment of high blood pressure and edema. It is no longer available in the United States. As a diuretic, benzthiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. The following is a list of possible side effects that may occur from all constituting ingredients of Exna Tablet: vomiting, diarrhoea, photosensitivity reactions, increased in uric acid concentrations, megaloblastic anaemia, thrombocytopenia. Exna tablet may interact with the following drugs and products: ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics.
Originator
Sources: http://www.drugfuture.com/chemdata/BENZTHIAZIDE.html
Curator's Comment: Pfizer https://www.google.ch/patents/US3440244
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16858005 |
0.0167 µM [Kd] | ||
Target ID: CHEMBL1876 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14766743 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EXNA Approved UseManagement of mild to moderate hypertension; treatment of edema in congestive heart failure and nephrotic syndrome Launch Date1960 |
|||
Sources: http://edudrugs.com/A/Aquatag/more.html |
Primary | EXNA Approved UseManagement of mild to moderate hypertension; treatment of edema in congestive heart failure and nephrotic syndrome Launch Date1960 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h |
unknown, oral |
BENZTHIAZIDE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
90% |
unknown, oral |
BENZTHIAZIDE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
inconclusive [Activation 12.5893 uM] | ||||
inconclusive [Activation 3.9811 uM] | ||||
no [Activation 12.5893 uM] | ||||
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
yes [Activation 12.5893 uM] | ||||
yes [IC50 5.743 uM] | ||||
yes [Inhibition 10 uM] | ||||
yes [Inhibition 10 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Assessment of different protocols for the isolation and purification of gut associated lymphoid cells from the gilthead seabream (Sparus aurata L.). | 2007 Nov 25 |
|
Combined effect of solvent content, temperature and pH on the chromatographic behaviour of ionisable compounds. | 2007 Sep 7 |
|
Capillary electrophoresis of diuretics and probenecid in methanol. | 2008 Jul 11 |
|
Expression profile of CREB knockdown in myeloid leukemia cells. | 2008 Sep 18 |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
The neuropharmacology of implicit learning. | 2010 Dec |
Sample Use Guides
Hypertension: 50-100 mg/day; maintenance: individualize dose (maximum effective dose: 200 mg/day)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13760527
Carbon dioxide protects the carbonic anhydrase from inhibition by benzthiazide. After equilibration
of inhibitor with enzyme in the presence of substrate, an inhibition is observed at a drug concentration 100-fold higher than that required for a similar inhibition after equilibration in the absence of substrate.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C49185
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
332
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
1TD8J48L61
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
Benzthiazide
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
755902
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
DTXSID4022658
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
3047
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
SUB05769MIG
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
100000086394
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
BENZTHIAZIDE
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
944
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
2343
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
3296
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
m2393
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
202-061-0
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
19008
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
C004463
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
7125
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
C65254
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
DB00562
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201039
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY | |||
|
91-33-8
Created by
admin on Fri Dec 15 15:17:38 GMT 2023 , Edited by admin on Fri Dec 15 15:17:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY